Aortic Regurgitation: What You Need to Understand

2. What It Is

Aortic regurgitation (AR) is incompetence of the aortic valve, allowing retrograde flow of blood from the aorta into the left ventricle during diastole. The LV receives its normal ventricular filling from the left atrium plus the regurgitant volume flowing back from the aorta, creating a volume overload state rather than the pressure overload of aortic stenosis.

AR is graded 1 to 4+ (Sellers grading) or by 2021 valve guideline stages:

• Mild AR: Small regurgitant jet, regurgitant fraction below 30%, vena contracta below 3 mm
• Moderate AR: Regurgitant fraction 30-49%, vena contracta 3-6 mm
• Severe AR: Regurgitant fraction above 50%, vena contracta above 6 mm, effective regurgitant orifice above 0.30 cm2

The distinction between acute and chronic AR is fundamental, because the pathophysiology, presentation, and urgency of management differ completely.

Causes

Chronic AR causes:

• Bicuspid aortic valve (congenital): leaflet prolapse or incomplete coaptation, often in young adults
• Aortic root dilation: Any condition that enlarges the aortic root stretches the annulus, pulling the leaflets apart. This includes hypertension, Marfan syndrome, Loeys-Dietz syndrome, and degenerative aortopathy
• Rheumatic heart disease: Leaflet retraction and commissural fusion; more common globally
• Degenerative calcific AR: In older adults with calcific disease; often coexists with AS

Acute AR causes:

• Type A aortic dissection: The dissection flap can displace a coronary cusp below the annulus, preventing leaflet coaptation; this is the most hemodynamically dangerous acute AR scenario
• Infective endocarditis: Vegetation or leaflet perforation
• Trauma: Blunt chest injury causing leaflet rupture

3. The Mechanism

Chronic AR: the compensated volume overload

In chronic severe AR, the LV receives a large regurgitant volume every diastole. The total LV stroke volume must equal the forward stroke volume (what goes out to the body) plus the regurgitant volume (what comes back from the aorta). To handle this increased volume, the LV dilates eccentrically (increases cavity size) and hypertrophies: both volume and mass increase, but the ratio of wall thickness to radius is maintained (unlike the concentric hypertrophy of AS). This eccentric hypertrophy is the LV’s attempt to normalize wall stress while accepting increased preload. EF is typically preserved or even raised in compensated AR.

The compensated state can last for years or decades. The heart enlarges progressively, accommodating the regurgitant volume without symptoms. This is the deceptively benign phase. The danger: the LV is remodeling continuously. The myocyte architecture is changing. Fibrosis accumulates silently. At some point, the LV becomes unable to fully compensate, and EF begins to fall.

The critical window is when EF falls from supranormal or normal to the high-normal range (58-65%). This early EF decline, while still “within normal,” may signal early irreversible myocardial dysfunction. Once EF falls below 50-55% in chronic AR, reoperation for early LV dysfunction is often too late for full recovery.

Acute AR: the hemodynamic catastrophe

In acute AR (from dissection or endocarditis), there is no time for LV remodeling. The LV is suddenly required to handle a large regurgitant volume in a chamber that has not dilated to accommodate it. The resulting acute volume overload dramatically raises LVEDP. The LV cannot eject adequately against the raised filling pressure. Acute pulmonary edema develops rapidly. Heart rate soars compensatorily. Diastolic blood pressure falls (aortic run-off into the LV). The pulse pressure widens to extreme values.

Clinically: the patient with acute severe AR presents in acute pulmonary edema, tachycardia, with a soft or inaudible diastolic murmur (because the LV and aortic pressures equalize rapidly, reducing the pressure gradient driving the regurgitant jet). The absence of a loud murmur in a patient with acute severe AR is a trap.

Acute Type A dissection with AR is a surgical emergency: repair must occur within hours. Infective endocarditis-related acute AR requires urgent cardiac surgery evaluation.

4. How We Diagnose

Auscultation

Chronic AR: high-pitched, blowing, decrescendo diastolic murmur at left sternal border (3rd intercostal space), best heard with the diaphragm of the stethoscope and with the patient leaning forward and in expiration. Radiation to the right sternal border suggests root dilation (aortic root disease). The Austin Flint murmur is a mid-to-late diastolic rumble at the apex from the regurgitant jet pushing the mitral leaflet into a partially closed position, mimicking mitral stenosis.

Peripheral signs of severe chronic AR:

• Corrigan pulse (water hammer): Rapid upstroke and abrupt collapse of the carotid pulse
• Quincke pulse: Pulsatile nail bed capillary filling seen with finger compression
• de Musset sign: Head nodding with each heartbeat
• Hill sign: Popliteal blood pressure exceeds brachial by more than 20 mmHg (reflecting wide pulse pressure in peripheral circulation)

These peripheral signs reflect the wide pulse pressure (raised systolic, reduced diastolic) from the combination of high forward stroke volume (raised systolic) and aortic diastolic run-off (reduced diastolic).

Echocardiography

TTE provides:

• AR severity (Sellers grading, vena contracta, regurgitant fraction, pressure half-time)
• LV dimensions: end-diastolic and end-systolic diameter (the primary surgical thresholds)
• LV volumes and EF
• Aortic root dimensions at four levels: annulus, sinuses of Valsalva, sinotubular junction, ascending aorta
• Cause of AR (bicuspid valve, leaflet prolapse, root dilation)

Serial echocardiography every 6-12 months for severe asymptomatic AR is the standard surveillance protocol.

CMR provides more accurate quantification of regurgitant fraction and LV volumes when echocardiographic windows are poor or when the decision about surgery timing depends on precise volume measurements.

Cardiac CT or TEE for pre-surgical planning or to evaluate the ascending aorta when dilation is present.

5. The Evidence

The natural history: watchful waiting in asymptomatic chronic severe AR

Multiple observational studies have established the natural history of asymptomatic severe AR:

• In the Bonow series (n=104, JACC 2007; 10.1016/j.jacc.2007.04.049), the rate of developing symptoms or LV dysfunction in asymptomatic severe AR patients was approximately 6% per year over 10 years of follow-up 5 / Solid . Annual development of symptoms necessitating surgery occurred in approximately 4-6% per year.
• LV systolic dysfunction developed in approximately 3% per year.
• The most powerful predictors of progression: LV end-systolic diameter above 50 mm and initial LV dimensions at the high end of normal.

AVATAR trial: early surgery vs watchful waiting in asymptomatic severe AR (2022)

The AVATAR trial enrolled 157 asymptomatic patients with severe AR and EF above 60% and randomized them to early surgery versus watchful waiting 4 / Promising . After a median follow-up of 4 years, early surgery reduced the composite of all-cause mortality, acute MI, stroke, and hospitalization for HF compared to watchful waiting (HR 0.46, 95% CI 0.23-0.94, p = 0.03). This is the first RCT for early surgery in asymptomatic AR. The trial was underpowered and had enrollment challenges, but the direction is consistent with RECOVERY trial findings in AS: earlier intervention in severe asymptomatic valve disease may improve outcomes compared to watchful waiting.

TAVR for aortic regurgitation: limited and evolving data

TAVR was designed for stenotic valves; the absence of calcification in many AR etiologies makes valve anchoring difficult (no calcified landing zone for the prosthesis). The JenaValve (which clips to the native aortic leaflets) and dedicated TAVR-for-AR devices are in clinical trials. Registry data shows acceptable technical success but higher rates of significant residual regurgitation and pacemaker compared to AS-TAVR 3 / Early 69208-9; TAVR-AR registries DOI pending verification). TAVR for AR is off-label in most US centers and reserved for inoperable patients.

Medical therapy

No pharmacological therapy has been proven to delay the need for surgery in chronic AR with preserved EF. Older observational data suggested vasodilators (nifedipine, hydralazine) might slow LV remodeling, but the NEJM 1994 RCT by Scognamiglio showed no benefit, and the 2005 Evangelista randomized trial showed no benefit from ACE inhibitors 5 / Solid . Current guidelines do not recommend vasodilator therapy to delay surgery in asymptomatic AR with preserved EF.

Vasodilators are appropriate for acute severe AR as a bridge to surgery (IV nitroprusside or IV nitroglycerin to reduce afterload and improve forward flow while the patient is being prepared for the operating room).

6. The Patient Experience

The patient with chronic severe AR is in a psychological position similar to the patient with asymptomatic severe AS: told they have a serious valve problem, advised to watch and wait, and left to wonder what “watch and wait” means in practice.

The physical signs of chronic severe AR (the bounding Corrigan pulse, the head nodding, the pulsation visible in the neck) can be distressing to observe and to learn about. Patients sometimes become hyper-vigilant about their heart rate and pulse, catastrophizing normal palpitations.

The surgeon’s conversation with an asymptomatic AR patient who has reached a dimension threshold is one of the harder valve conversations: “Your heart is enlarging. Your numbers have not yet crossed the threshold, but the trend is heading there. We need to decide soon whether surgery now is better than waiting for symptoms that may arrive with irreversible damage.” This conversation requires the patient to act on a future risk, not a present emergency.

Surgery for AR typically involves repair of the valve (when feasible) or replacement. The David procedure and Yacoub procedure are valve-sparing aortic root replacements for patients with AR due to root dilation and anatomically normal leaflets. These spare the native valve while replacing the dilated root, avoiding the need for anticoagulation. Valve-sparing root replacement at experienced centers has excellent durability data (85-90% freedom from reoperation at 10 years) 5 / Solid .

7. Decisions and Trade-Offs

Surgery thresholds for asymptomatic severe AR

The 2021 ACC/AHA valve guidelines specify Class 1 (recommended) indications for surgery in asymptomatic severe AR:

• EF below 55%
• LV end-systolic diameter above 50 mm (index to BSA above 25 mm/m2 for smaller patients)

Class 2a (reasonable) indications:

• Progressive LV dilation on serial imaging (LVEDD above 65 mm)
• At the time of other cardiac surgery

In the software engineer’s case: ESD of 4.6 cm (46 mm) is below the 50 mm Class 1 threshold. LVEDD of 6.3 cm (63 mm) is approaching the 65 mm Class 2a threshold. Annual surveillance with discussion at each visit is the current standard. If ESD reaches 50 mm or LVEDD reaches 65 mm, surgery becomes the Class 1 or 2a recommendation.

The role of exercise testing

Symptom status in asymptomatic AR can be unreliable: patients with gradual LV dilation have a subconscious adaptation of their activity level to avoid symptoms. Exercise stress testing with echocardiography can unmask hemodynamic dysfunction (EF fails to rise normally with exercise; LVESD increases with exertion) or symptoms, reclassifying the patient from “asymptomatic” to “functionally symptomatic” and advancing the surgical indication.

Aortopathy considerations

For patients with AR secondary to aortic root dilation (particularly in Marfan syndrome, Loeys-Dietz syndrome, or BAV-associated aortopathy), the size of the ascending aorta determines surgical timing as much as the valve AR severity.

Current aortopathy surgery thresholds:

• General population: aorta above 5.5 cm
• Bicuspid aortic valve: above 5.0 cm (or 4.5 cm with rapid growth, family history of dissection, or planned valve surgery)
• Marfan syndrome: above 5.0 cm (or 4.5 cm with family history of dissection, rapid growth)

The patient with a 4.8 cm ascending aortic aneurysm and severe AR from a bicuspid valve may be offered surgery for the combined valve and root pathology even if the AR alone would not yet meet surgical thresholds.

Medical therapy and the rate of AR progression

There is no proven pharmacological therapy that slows AR progression or delays the need for surgery in asymptomatic patients with normal LV function. Vasodilators (ACE inhibitors, ARBs, dihydropyridine calcium channel blockers) reduce afterload and may reduce regurgitant volume modestly, but they have not demonstrated a mortality or surgery-delay benefit in randomized trials 5 / Solid . They are indicated for hypertension management in AR patients but should not be prescribed under the premise that they substitute for surgical surveillance or delay the need for valve replacement.

Beta-blockers are not routinely indicated for asymptomatic AR with normal LV function and normal sinus rhythm. They may be appropriate for coexisting hypertension, rate control in AF, or symptom management, but they do not reduce AR severity.

AR and infective endocarditis

Aortic regurgitation from infective endocarditis is a distinct surgical emergency scenario. Leaflet destruction from endocarditis can convert chronic compensated AR to acute severe AR overnight. Acute severe AR (rapid LV pressure equalization, pulmonary edema) does not tolerate the usual watchful waiting approach: the LV cannot dilate acutely to compensate. Emergency or urgent aortic valve replacement is the treatment. The clinical clues: fever, new AR murmur, and pulmonary edema in a patient without prior AR history should trigger immediate echocardiography and infectious disease consultation.

8. The SDE Synthesis

Aortic regurgitation is the valve disease most at risk of the “stable” illusion. The LV accommodates a massive volume overload silently for years, the patient remains asymptomatic, and the echo is reported as “stable” when in fact the ventricle has been enlarging by 2-3 mm per year for a decade. By the time symptoms arrive, the LV may be irreversibly dilated.

The SDE Audit is designed to catch this trajectory before the threshold is crossed. Serial echocardiographic measurement, trended over time with explicit comparison to prior studies (not just a single-point assessment), reveals the rate of LV enlargement in ways that an annual verbal report of “stable” does not.

For patients with established chronic severe AR in the asymptomatic phase, the SDE Cohort provides the systematic follow-up structure: annual echocardiography, trending of LV dimensions, proactive surgical consultation when dimensions approach guideline thresholds.

For patients with BAV aortopathy, aortic root surveillance is a parallel track to the AR severity assessment. The SDE Audit includes aortic diameter measurement at four standard levels, enabling early detection of aortopathy that warrants pre-emptive surgical referral.

Cardiac surgery for AR in Illinois at experienced centers: Northwestern Memorial Hospital (Bluhm Cardiovascular Institute), University of Chicago Medical Center, and Rush University Medical Center all offer valve-sparing procedures in addition to standard valve replacement. The David procedure for root dilation AR in young patients (below 50) with normal leaflets is available at these centers.

The software engineer from Chicago will reach a decision point within the next 18-24 months based on his current trajectory. He deserves a cardiologist who can explain it to him now, while the operation is elective, rather than the week his ESD crosses 5.0 cm.